In-Licensing Lessons: Benchmarking Best Practice | Evaluate
Leverage biotechs for pipeline boost with reduced risk. Navigate the large ecosystem to select assets fitting your strategy for successful partnerships.| Evaluate
Leverage biotechs for pipeline boost with reduced risk. Navigate the large ecosystem to select assets fitting your strategy for successful partnerships.| Evaluate
Andrew Ward discusses the role of analogs in pharmaceutical forecasting and shares best practices their successful use in this short video.| Evaluate
Discover how pharma and biotech are converging in a consumer-driven landscape. Learn about direct-to-patient models, carve-out deals, and why some biotechs are going solo. Get early access to insights from “Pharma v Biotech: New Rules?” and stay ahead of the curve.| Evaluate
Discover how biotech and Big Pharma are evolving under pressure. From China’s R&D surge to pricing reform, we reveal key market shifts that are reshaping the pharma landscape.| Evaluate
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
Discover how a configurable treatment value model empowers pharmaceutical companies, healthcare professionals, and patients in emerging therapeutic markets—enhancing drug launch strategies, treatment access, and clinical decision-making with real-world data and cost transparency.| Evaluate
Evaluate's pharmaceutical consulting and analytics team provide expert solutions for your unique scientific, clinical, and commercial challenges, enhancing your strategy.| Evaluate
Andrew Ward discusses the continued relevance of Excel-based forecasting as part of a forecasters software toolkit, highlighting its flexibility, transparency, and universal accessibility.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Discover how pharma forecasting teams can navigate Loss of Exclusivity (LoE) with precision. Learn strategies to manage asset saturation, biosimilar impact, and regional planning in today’s competitive pipeline landscape.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the biotech investment landscape..| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
Discover our comprehensive thought leadership library featuring the latest data-driven reports, captivating infographics, and insightful articles addressing key industry issues, niche topics, and everything in between.| Evaluate
Evaluate’s latest report features 2025 pharma forecasts for top-selling drugs, biggest companies and potential novel drug approvals for the year ahead.| Evaluate
Find out how Evaluate can help you - pharma & biotech, financial services, management consultancies, medtech & service providers to the pharma industry.| Evaluate
Access all the crucial insights you need with Competitive Landscape Analysis, facilitating risk assessment, uncovering unmet needs, and gaining deeper insights into your growth drivers and product differentiators. Empower your SEO strategy with these optimized descriptions.| Evaluate
Company Profiling helps you discover, profile, and track the ideal companies aligned with your growth strategy.| Evaluate
Evaluate Commercial Opportunity Assessment integrates company financials, product attributes, consensus forecasts, and market insights to guide your strategic product placement effectively.| Evaluate
Unlock accurate, unbiased, and timely insights into pharmaceutical asset potential through our solutions. Forecast product-level risks, costs, and timelines to empower confident commercial decision-making.| Evaluate
Utilize Evaluate for Market Opportunity Sizing to gain comprehensive insights into the potential clinical and commercial differentiation of new assets, their competitive landscape, and the market dynamics.| Evaluate
Leverage Evaluate's benchmarking and negotiation tools to gain insights into the dealmaking landscape, supported by extensive historical data for context.| Evaluate
